GlassScriptPhysician profile
Shankar Srinivasan
NPI 1093855728
$154,946.40
in general payments reported to CMS, 2019-2025
35 companies · $65K in 2025
The $65K reported for 2025 was more than what 98% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,042 · 2020: $506 · 2021: $4,226 · 2022: $6,341 · 2023: $39K · 2024: $38K · 2025: $65K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $78K · Honoraria: $37K · Consulting Fee: $16K · Food and Beverage: $7,475 · Travel and Lodging: $2,381 · Education: $30.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $78,457.50 |
| Honoraria | $37,088.00 |
| Consulting Fee | $16,400.00 |
| Food and Beverage | $7,475.33 |
| Travel and Lodging | $2,380.58 |
| Education | $30.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $81,082.59 | 2021-2025 | Vraylar |
| Axsome Therapeutics, INC. | $34,181.86 | 2023-2025 | Auvelity, Sunosi |
| Supernus Pharmaceuticals, INC. | $24,207.95 | 2021-2025 | Qelbree, Qelbree |
| Idorsia Pharmaceuticals US INC | $8,325.69 | 2022-2024 | Quviviq |
| Alkermes, INC. | $839.45 | 2021-2025 | Lybalvi, Aristada |
| Takeda Pharmaceuticals U.S.A., INC. | $688.48 | 2019-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $601.31 | 2019-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $481.10 | 2019-2024 | Spravato |
| Lundbeck LLC | $469.43 | 2019-2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $452.49 | 2019-2022 | |
| Neos Therapeutics, LP | $405.63 | 2019-2025 | Adzenys Xr-Odt, Exxua |
| Neuronetics, INC. | $375.27 | 2019-2024 | Neurostar Tms Therapy System |
| Teva Pharmaceuticals USA, INC. | $345.99 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $339.84 | 2020-2024 | Caplyta |
| Vanda Pharmaceuticals INC. | $273.65 | 2019-2025 | Fanapt |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $226.54 | 2022-2025 | Ingrezza |
| Jazz Pharmaceuticals INC. | $223.75 | 2019-2021 | |
| Bausch Health US, LLC | $211.12 | 2019-2024 | Aplenzin, Wellbutrin |
| Allergan, INC. | $208.48 | 2019-2020 | |
| Tris Pharma INC | $198.69 | 2019-2025 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $165.39 | 2019-2024 | Jornay Pm |
| Corium, LLC | $157.58 | 2022-2025 | Azstarys, Azstarys |
| Arbor Pharmaceuticals, INC. | $78.76 | 2019-2020 | |
| Adlon Therapeutics L.P. | $71.09 | 2019-2021 | |
| Vertical Pharmaceuticals, LLC | $67.81 | 2019 | |
| Almatica Pharma LLC | $54.38 | 2024-2025 | Loreev Xr |
| E.R. Squibb & Sons, L.L.C. | $50.43 | 2025 | Cobenfy |
| Indivior INC. | $33.07 | 2024 | Perseris |
| Collegium Pharmaceutical, INC. | $30.76 | 2025 | Jornay Pm |
| Shire North American Group INC | $25.77 | 2019 | |
| Alfasigma USA, INC. | $16.42 | 2020 | |
| Avanir Pharmaceuticals, INC. | $14.76 | 2020 | |
| Owp Pharmaceuticals, INC. | $13.97 | 2021 | |
| Eisai INC. | $13.86 | 2020 | |
| Biodelivery Sciences International, INC. | $13.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shankar Srinivasan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.